Abstract Background In March 2008, the D: A: D study published results demonstrating an
increased risk of myocardial infarction (MI) for patients on abacavir (ABC). We describe …

Southern Africa is the region worst affected by HIV in the world and accounts for one third of
the global burden of HIV. Achieving the UNAIDS 90-90-90 target by 2020 and ending the …

Background: Patients with HIV exposed to the antiretroviral drug abacavir may have an
increased risk of cardiovascular disease (CVD). There is concern that this association arises …

Background There is ongoing controversy regarding abacavir use in the treatment of HIV
infection and the risk of subsequent development of cardiovascular disease. It is unclear …

Prolonged survival in HIV infection is accompanied by an increased frequency of non‐HIV‐
related comorbidities. It is suggested that cardiovascular diseases (CVD) occur earlier …

Following cardiovascular events (CVE) among people living with HIV (PLWH) is essential.
Abacavir (ABC)'s impact on CVE challenges clinicians. We characterized CVE at our HIV …

CVD is an emerging health economic emergency. Following the successful introduction of
ART, PLWHIV have a close to normal life expectancy and are succumbing to traditional …

Увеличение продолжительности жизни у пациентов с инфекцией, вызванной вирусом
иммунодефицита человека (ВИЧ), сопровождается высокой частотой развития …

Background: More than thirty years after the beginning of the human immunodeficiency
virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic, HIV continues to be a …

Antiretroviral drugs are fundamental to the treatment of Human Immunodeficiency Virus
(HIV), effectively inhibiting viral replication, the emergence of Acquired Immune Deficiency …